Skip to content

A Study on Intelligent Diagnosis of Gleason Score and Pelvic Lymph Node Metastasis in Prostate Cancer Based on Radiomics of ¹8F-PSMA PET/CT Imaging

A Study on Intelligent Diagnosis of Gleason Score and Pelvic Lymph Node Metastasis in Prostate Cancer Based on Radiomics of ¹8F-PSMA PET/CT Imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119164
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Index test: The radiomics differential diagnosis model

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Male patients aged 18 years and above; 2.No anti-tumor treatment (surgery, chemotherapy, targeted therapy, immunotherapy, etc.) before PET/CT; 3.Pathologically confirmed PCa by surgery within 1 month post-examination, with complete prostate/lymph node pathology and preserved pathological sections; 4.Complete clinical and imaging data;

Exclusion criteria

Exclusion criteria: 1.Patients with negative ¹8F-PSMA PET/CT imaging findings; 2.Patients with poor image quality; 3.Patients who did not undergo lymph node dissection and without pathological gold standard for lymph node metastasis; 4.Patients with other concurrent malignant tumors;

Design outcomes

Primary

MeasureTime frame
Sensitivity;specificity;accuracy;positive predictive value;

Countries

China

Contacts

Public ContactLijuan Shen

Shanghai General Hospital

13817959783@163.com+86 21 3612 6311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026